



# DANMAP 2022

Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark



## DANMAP 2022

### **Editors:**

Ana Sofia Ribeiro Duarte  
Majda Attauabi  
Marianne Sandberg  
Mikkel Lindegaard  
Ute Wolff Sönksen  
Vibe Dalhoff Andersen

### **DANMAP Steering Committee:**

National Food Institute: Frank Møller Aarestrup, Marianne Sandberg  
Statens Serum Institut: Anders Rhod Larsen, Ute Wolff Sönksen

### **External reviewers:**

Cecilie Hviid Christiansen  
Christian Johann Lerche  
Inge Jenny Dahl Knudsen  
Jette Nygaard Jensen  
Joana Pessoa  
Jonas Bredtoft Boel  
Malene Plejdrup Hansen

### **Contact:**

Ana Sofia Ribeiro Duarte (asrd@food.dtu.dk)  
National Food Institute,  
Technical University of Denmark  
Kemitorget, Building 204, DK-2800 Kgs. Lyngby

Ute Wolff Sönksen (uws@ssi.dk)  
Diagnostic Infectious Disease Preparedness  
Statens Serum Institut  
Artillerivej 5, DK-2300 Copenhagen

**Layout:** Anja Bjarnum, Statens Serum Institut

**Photos:** Colourbox

**Printing:** Pekema A/S

DANMAP 2022 - November 2023 - ISSN 1600-2032

### **Text and tables may be cited and reprinted only with reference to this report:**

DANMAP 2022 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. ISSN 1600-2032

The report is available from [www.danmap.org](http://www.danmap.org)

# DANMAP 2022

Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark

# Table of contents

<b>1. Editorial</b>	<b>9</b>
<b>2. Introduction to DANMAP</b>	<b>11</b>
2.1 The DANMAP surveillance system	12
2.2 Information on demographics and health care system	14
2.3 Information on animal population and food production system	16
2.4 Registered antimicrobial agents	16
<b>3. One Health AMR</b>	<b>19</b>
3.1 Introduction	20
3.2 Genotypic comparison of ESBL/AmpC-producing <i>E. coli</i> from humans, animals and food	20
Textbox 3.1 Flankophile: A bioinformatics pipeline for prokaryotic genomic synteny analysis	23
<b>4. Antimicrobial consumption in animals</b>	<b>25</b>
4.1 Introduction	27
4.2 Total antimicrobial consumption in animals	29
4.3 Antimicrobial consumption by animal species	31
Textbox 4.1 No more high dose zinc oxide in veterinary medicinal products	42
Textbox 4.2 New EU legislation on veterinary medicinal products	43
Textbox 4.3 Faecal microbiota transplantation for prevention of diarrhoea in pigs	44
<b>5. Antimicrobial consumption in humans</b>	<b>47</b>
5.1 Introduction	49
5.2 Total antimicrobial consumption in the Danish healthcare system	50
5.3 Antimicrobial consumption in primary health care	53
5.4 Antimicrobial consumption at hospitals	65
Textbox 5.1 Comparison of antibiotic prescribing for elderly in long-term care facilities and elderly living at home	74
Textbox 5.2 Sociodemographic characterisation of antibiotic heavy users in the Danish elderly population	76
Textbox 5.3 Incidence of multiresistant bacteria and consumption of antimicrobial agents in Greenland	78
Textbox 5.4 Shortage of antibiotics at Community Pharmacies in Denmark	81
Textbox 5.5 Research Units for General Practice in Denmark	85
<b>6. Resistance in zoonotic bacteria</b>	<b>87</b>
6.1 Introduction	89
6.2 <i>Campylobacter</i>	89
6.3 <i>Salmonella</i>	91
Textbox 6.1 Detection of resistance genes and point mutations in <i>Salmonella</i> and <i>Campylobacter</i> using whole genome sequencing	95
<b>7. Resistance in indicator bacteria</b>	<b>99</b>
7.1 Introduction	101
7.2 Indicator <i>Escherichia coli</i>	101
7.3 ESBL/AmpC- and carbapenemase-producing <i>E. coli</i>	103
7.4 Indicator Enterococci	107
Textbox 7.1 Antimicrobial resistance trends in indicator <i>E. coli</i> in Danish pigs, broilers, and cattle 2014 to 2022	109
<b>8. Resistance in human pathogens</b>	<b>113</b>
8.1 Introduction	115
8.2 Results from MiBa data surveillance	118
8.2.1 <i>Escherichia coli</i>	118
8.2.2 <i>Klebsiella pneumoniae</i>	122
8.2.3 <i>Pseudomonas aeruginosa</i>	126

8.2.4	<i>Acinetobacter</i> species	127
8.2.5	Enterococci	128
8.3	Results from the reference laboratories	130
8.3.1	Characterization of ESBL- and pAmpC-producing <i>Escherichia coli</i> from bloodstream infections	130
8.3.2	Carbapenemase-producing organisms (CPO)	132
8.3.3	Vancomycin-resistant/vancomycin-variable enterococci	137
8.3.4	Detection of linezolid-resistant enterococci and linezolid-vancomycin-resistant enterococci	140
8.3.5	<i>Staphylococcus aureus</i>	141
8.3.6	<i>Streptococcus pneumoniae</i>	146
8.3.7	Beta-haemolytic streptococci	148
8.3.8	<i>Neisseria gonorrhoeae</i>	149
8.3.9	<i>Haemophilus influenzae</i>	153
8.3.10	Meningococci	154
Textbox 8.1	Dicloxacillin capsules contaminated with CPE in Denmark and Iceland	158
Textbox 8.2	Fungaemia epidemiology, resistance rates and human antifungal consumption: a 2021-2022 update	160
Textbox 8.3	<i>Mycoplasma genitalium</i>	163
<b>9.</b>	<b>Resistance in animal pathogens</b>	<b>165</b>
9.1	Introduction	167
9.2	Temporal trends of AMR in pathogenic bacteria from pigs	167
9.3	WGS-based detection of resistance genes and point mutations	170
9.4	WGS-based prediction of AMR	173
9.5	Conclusions and perspectives	174
Textbox 9.1	Antimicrobial resistance in dogs and cats: focus on extended-spectrum cephalosporinase-producing <i>Escherichia coli</i> and their resemblance to human clinical isolates	175
Textbox 9.2	Insights into the genetic basis of neomycin resistance in clinical <i>Escherichia coli</i> isolated from pigs	178
Textbox 9.3	Assessing the burden of Antimicrobial Resistance and Usage in the Global Burden of Animal Disease programme: the start of the Danish case study	181
<b>10.</b>	<b>Materials and methods</b>	<b>183</b>
10.1	General information	184
10.2	Data on antimicrobial consumption in animals	184
10.3	Collection of bacterial isolates from animals and meat	186
10.4	Microbiological methods - isolates from animals and meat	187
10.5	Susceptibility testing - isolates from animals and meat	188
10.6	Whole genome sequencing - isolates from animals and meat	188
10.7	Data handling - isolates from animals and meat	188
10.8	Data on antimicrobial consumption in humans	191
10.9	<i>Salmonella</i> and <i>Campylobacter</i> isolates from humans	192
10.10	<i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , <i>Pseudomonas aeruginosa</i> , <i>Acinetobacter</i> species, <i>Enterococcus faecium</i> and <i>Enterococcus faecalis</i> isolates from humans	193
10.11	ESBL-producing bacterial isolates from humans	193
10.12	CPO isolates from humans	194
10.13	VRE isolates from humans	194
10.14	Invasive <i>Streptococcus pneumoniae</i> isolates from humans	194
10.15	Isolates of beta-haemolytic streptococci of groups A, B, C, and G from invasive infections in humans	195
10.16	Invasive <i>Haemophilus influenzae</i> isolates from humans	196
10.17	<i>Staphylococcus aureus</i> including MRSA isolates from humans	196
10.18	Gonococci isolates	197
<b>11.</b>	<b>Terminology</b>	<b>199</b>
	List of abbreviations	200
	Glossary	201